Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.

REVIEWS IN MEDICAL VIROLOGY is a premier academic journal published by Wiley, dedicated to advancing the field of virology and infectious diseases. Established in 1991, this journal has gained a reputable standing, holding a Q1 ranking in both Infectious Diseases and Virology as of 2023, with impressive Scopus rankings placing it at #17 out of 344 in the realm of Medicine - Infectious Diseases, and #8 out of 80 in Immunology and Microbiology - Virology. This reflects its substantial impact factor and contribution to ongoing research and scholarship. While it is not an Open Access publication, REVIEWS IN MEDICAL VIROLOGY offers vital insights and comprehensive reviews that cater to a diverse audience including researchers, healthcare professionals, and students pursuing knowledge in medical virology. The journal serves as a vital resource for understanding the complexities of viral pathogens and the evolving landscape of antiviral therapeutics, making it an essential read for those poised at the forefront of infectious disease research.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

Food and Environmental Virology is a distinguished journal published by SPRINGER, focusing on the intersection of virology, food science, and environmental health. With its ISSN 1867-0334 and E-ISSN 1867-0342, this journal stands out for its contributions to the understanding of viral pathogens affecting food safety and environmental sustainability. Operating from its esteemed location in New York, USA, the journal has made significant strides since its inception in 2009, with a converged publication period extending to 2024. It currently holds a commendable position within various categories, ranking Q3 in Epidemiology and Virology and Q2 in both Food Science and Health, Toxicology and Mutagenesis, indicating its crucial role in informing both research and policy in these fields. With impressive Scopus rankings—such as 82nd out of 389 in Food Science and 38th out of 148 in Epidemiology—Food and Environmental Virology continues to be a vital resource for researchers, professionals, and students committed to advancing knowledge and practices around food safety and public health. While it operates under a subscription model, the rigorous peer-review process ensures that only high-quality research is published, maintaining the journal’s integrity and relevance in the scientific community.

JOURNAL OF MEDICAL VIROLOGY is a prestigious academic publication dedicated to advancing the field of virology and infectious diseases. Published by WILEY, this journal has established itself as a cornerstone within the scientific community since its inception in 1977, and it will continue to provide cutting-edge research until 2024. With an impressive impact factor that places it in the Q1 quartile for both Infectious Diseases and Virology, the journal ranks 14 out of 344 in Medicine - Infectious Diseases and 6 out of 80 in Immunology and Microbiology - Virology according to Scopus metrics. Its focus encompasses a broad spectrum of topics, including viral pathogenesis, diagnostics, treatment strategies, and epidemiology, making it an essential resource for researchers, clinicians, and students alike. Although not an open-access journal, it provides valuable insights and accessible content for subscribers and libraries. The ongoing commitment to high-quality peer-reviewed articles makes JOURNAL OF MEDICAL VIROLOGY a vital platform for disseminating knowledge and fostering innovation in virology and related fields.

Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

Tumour Virus Research, an esteemed journal published by Elsevier, serves as a vital resource in the fields of cancer research, infectious diseases, and virology. With an impact factor reflective of its influence and recognized as a Q2 journal in multiple categories as of 2023, it rigorously presents high-impact research dedicated to the understanding of viral pathogens in tumorigenesis. Since its transition to an Open Access model in 2021, the journal has enhanced accessibility, empowering researchers and the academic community globally to explore cutting-edge findings. The journal covers a broad scope, encompassing the intricate interactions between viruses and cancer biology, which is crucial for developing novel therapeutic strategies. With a commitment to advancing scientific knowledge, Tumour Virus Research welcomes submissions that push the boundaries of current understanding and contribute to the ongoing battle against virus-mediated cancers, making it an indispensable publication for professionals, researchers, and students in the field.

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.